X

Trial Profile

Phase II Study of GW786034 in Patients With Relapsed or Refractory Soft Tissue Sarcoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 Jun 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pazopanib (Primary)
Indications Leiomyosarcoma; Soft tissue sarcoma
Focus Therapeutic Use
Sponsors GlaxoSmithKline; GSK

Most Recent Events

18 May 2019 Trial has been completed in UK.
14 Feb 2019 Results evaluating coadministration of long term gastric acid suppressive agents therapy with pazopanib published in the Clinical Cancer Research
12 Sep 2017 Results (n=333) of EORTC62043 and EORTC62072 trials assessing evolution in neutrophil to lymphocyte ratio in patients with advanced soft tissue sarcoma, presented at the 42nd European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com